摘要
目的探讨microRNA-429与稳定型冠心病患者冠状动脉病变和心肌损伤相关指标之间的关系。方法选取2018年8月至2019年8月我院心血管内科收治并确诊为稳定型冠心病的患者120例作为研究对象,根据冠状动脉病变程度评分,将所有的入组对象分为轻度病变组(≤30分)和重度病变组(>30分),检测患者血清microRNA-429表达水平及心肌损伤相关指标,进一步分析microRNA-429表达水平与冠状动脉病变及心肌损伤相关指标的关系。结果两组患者间Gensini积分差异具有统计学意义(P<0.05);相对于轻度病变组,重度病变组患者体内microRNA-429表达水平显著升高,差异具有统计学意义(P<0.01);重度病变组患者的血清CK-MB、CRP及IL-6表达水平均明显大于轻度病变组(P<0.05);通过Pearson相关性分析结果显示,患者组血清microRNA-429表达水平与Gensini积分、CK-MB、CRP及IL-6间均存在明显正相关,且具有统计学意义(P<0.05);ROC工作曲线显示,microRNA-429表达水平对冠脉病变的严重程度有一定的预测价值,AUC为0.828(95%CI:0.668~0.969,P=0.004),灵敏度为86.38%,特异性为65.12%。结论稳定型冠心病患者体内存在microRNA-429的表达水平上调,且与冠状动脉病变程度和心肌损伤相关指标关系密切,可作为评估疾病进展的预测指标。
Objective To investigate the relationship between microRNA-429 and coronary and related indexes of myocardial injury in patients with stable coronary heart disease.Methods From August,2018 to August,2019,120 patients with stable coronary heart disease were selected as the research objects.According to the degree of coronary lesions,all these subjects were divided into the mild lesion group(≤30 points)and severe lesion group(>30 points).The expression of serum microRNA-429 and the related indexes of myocardial injury were measured in all patients,and further analysis of the relationship between microRNA-429 expression and coronary lesions and related indexes of myocardial injury was conducted.Results There was a significant difference in Gensini score between the two groups(P<0.05);The expression of microRNA-429 in patients with severe lesions was significantly higher than that in patients with mild lesions(P<0.01);There was a significant positive correlation between the expression of microRNA-429 and Gensini score,CK-MB,CRP and IL-6(P<0.05);ROC curve showed that the expression level of microrna-429 had a certain predictive value for the severity of coronary artery disease,with AUC 0.828(95%CI:0.668-0.969,P=0.004),sensitivity 86.38%,and specificity 65.12%.Conclusion The expression of microRNA-429 is up-regulated in patients with stable coronary heart disease,which is closely related to the degree of coronary lesions and myocardial injury,and can be used as a predictor of disease progress.
作者
冯莉莉
王朝华
李贺
张臣
FENG Lili;WANG Chaohua;LI He;ZHANG Chen(Department of Cardiology,Hunan Brain Hospital,Changsha 410007,China)
出处
《标记免疫分析与临床》
CAS
2022年第4期657-660,704,共5页
Labeled Immunoassays and Clinical Medicine